Roche and Biogen Idec's ocrelizumab positive in first Phase III trial for RA
This article was originally published in Scrip
Executive Summary
Roche and Biogen Idec's humanised anti-CD20 monoclonal antibody ocrelizumab has met the primary endpoint of its first Phase III study in rheumatoid arthritis (RA), top-line data of the STAGE trial show.